[go: up one dir, main page]

MX2017014001A - Analogos de nucleosidos 5 ' -sustituidos. - Google Patents

Analogos de nucleosidos 5 ' -sustituidos.

Info

Publication number
MX2017014001A
MX2017014001A MX2017014001A MX2017014001A MX2017014001A MX 2017014001 A MX2017014001 A MX 2017014001A MX 2017014001 A MX2017014001 A MX 2017014001A MX 2017014001 A MX2017014001 A MX 2017014001A MX 2017014001 A MX2017014001 A MX 2017014001A
Authority
MX
Mexico
Prior art keywords
cancer
compounds
substituted nucleoside
nucleoside analogs
cholangiocarcinoma
Prior art date
Application number
MX2017014001A
Other languages
English (en)
Inventor
Andrew Woods Timothy
Morgan Watson Brian
S Cortez Guillermo
Quyoom Bonday Zahid
Robert Dahnke Karl
John Grogan Michael
Rodriguez Hergueta Antonio
Andrew Jamison James
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MX2017014001A publication Critical patent/MX2017014001A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/14—Pyrrolo-pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a compuestos de nucleósidos. 5'-sustituidos novedosos, composiciones farmacéuticas que comprenden los compuestos y métodos de utilización de los compuestos para tratar el cáncer, más particularmente para el tratamiento del cáncer, en particular los glioblastomas, melanoma, sarcomas, cáncer gástrico, cáncer de páncreas, colangiocarcinoma, cáncer de vejiga, cáncer de mama, cáncer de pulmón de células no pequeñas, leucemias, incluyendo leucemia mieloide aguda y los linfomas.
MX2017014001A 2015-05-04 2016-04-27 Analogos de nucleosidos 5 ' -sustituidos. MX2017014001A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15382225 2015-05-04
PCT/US2016/029475 WO2016178870A1 (en) 2015-05-04 2016-04-27 5'-substituted nucleoside analogs

Publications (1)

Publication Number Publication Date
MX2017014001A true MX2017014001A (es) 2018-03-16

Family

ID=53177322

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017014001A MX2017014001A (es) 2015-05-04 2016-04-27 Analogos de nucleosidos 5 ' -sustituidos.

Country Status (25)

Country Link
US (1) US9840532B2 (es)
EP (1) EP3292128A1 (es)
JP (2) JP6181889B1 (es)
KR (1) KR20170132871A (es)
CN (1) CN107580602A (es)
AR (1) AR104326A1 (es)
AU (1) AU2016258485A1 (es)
BR (1) BR112017020336A2 (es)
CA (1) CA2981097A1 (es)
CL (1) CL2017002637A1 (es)
CO (1) CO2017010727A2 (es)
CR (1) CR20170443A (es)
DO (1) DOP2017000255A (es)
EA (1) EA201792169A1 (es)
EC (1) ECSP17072987A (es)
HK (1) HK1244007A1 (es)
IL (1) IL254409A0 (es)
MA (1) MA42036A (es)
MX (1) MX2017014001A (es)
PE (1) PE20180231A1 (es)
PH (1) PH12017502002A1 (es)
SG (1) SG11201708345XA (es)
TN (1) TN2017000459A1 (es)
TW (1) TWI615400B (es)
WO (1) WO2016178870A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2792899T3 (es) * 2015-02-24 2020-11-12 Pfizer Derivados de nucleósidos sustituidos útiles como agentes anticancerosos
EP3574917A4 (en) * 2017-01-27 2020-05-06 University of Miyazaki Anti-cancer agent, method for screening for anti-cancer agent, kit for determination of efficacy on cancer, and method for determining efficacy on cancer
WO2018152548A1 (en) 2017-02-20 2018-08-23 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
WO2018152501A1 (en) 2017-02-20 2018-08-23 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
WO2018160855A1 (en) 2017-03-01 2018-09-07 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
PT3665179T (pt) 2017-08-09 2021-09-10 Prelude Therapeutics Inc Inibidores seletivos da proteína arginina metiltransferase 5 (prmt5)
EP3700906A1 (en) * 2017-10-26 2020-09-02 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
SMT202200396T1 (it) 2017-12-13 2022-11-18 Lupin Ltd Composti eterociclici biciclici sostituiti come inibitori di prmt5
US10711007B2 (en) 2018-03-14 2020-07-14 Prelude Therapeutics Incorporated Selective inhibitors of protein arginine methyltransferase 5 (PRMT5)
WO2019178368A1 (en) 2018-03-14 2019-09-19 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
JP7337539B2 (ja) * 2018-06-21 2023-09-04 メディヴィル・アクチエボラーグ 白血病療法のための塩基修飾シチジンヌクレオチド
WO2020033285A1 (en) * 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
KR20210129051A (ko) * 2019-02-13 2021-10-27 프렐루드 테라퓨틱스, 인코포레이티드 단백질 아르기닌 메틸트랜스퍼라제 5(prmt5)의 선택적 억제제
EP3980417B1 (en) 2019-06-10 2023-09-27 Lupin Limited Prmt5 inhibitors
JP7706166B2 (ja) * 2019-09-18 2025-07-11 プレリュード・セラピューティクス・インコーポレイテッド タンパク質アルギニンメチルトランスフェラーゼ５（ｐｒｍｔ５）の選択的阻害剤
AU2020371295A1 (en) 2019-10-22 2022-04-28 Lupin Limited Pharmaceutical combination of PRMT5 inhibitors
BR112022010943A2 (pt) 2019-12-03 2022-10-11 Lupin Ltd Análogos de nucleosídeos substituídos como inibidores de prmt5
GB202117230D0 (en) 2021-11-29 2022-01-12 Argonaut Therapeutics Ltd Peptide vaccine
GB202203588D0 (en) 2022-03-15 2022-04-27 Argonaut Therapeutics Ltd Cancer diagnostic
CN116211869B (zh) * 2022-12-07 2023-08-01 浙江省肿瘤医院 含dna损伤修复抑制剂的药物混合物及混合方法、用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1212326A4 (en) 1999-08-27 2003-08-20 Icn Pharmaceuticals NUCLEOSIDE ANALOGS OF PYRROLO 2,3-d] PYRIMIDINE
NZ544187A (en) * 2005-12-15 2008-07-31 Ind Res Ltd Deazapurine analogs of 1'-aza-l-nucleosides
WO2011079236A1 (en) 2009-12-22 2011-06-30 The Ohio State University Research Foundation Compositions and methods for cancer detection and treatment
WO2013009735A1 (en) 2011-07-13 2013-01-17 Merck Sharp & Dohme Corp. 5'-substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
LT2935222T (lt) 2012-12-21 2018-12-27 Epizyme, Inc. Prmt5 slopikliai ir jų panaudojimas
US9611257B2 (en) * 2012-12-21 2017-04-04 Epizyme, Inc. PRMT5 inhibitors and uses thereof
US20150344457A1 (en) 2012-12-21 2015-12-03 Epizyme, Inc. Methods of inhibiting prmt5
JP2016505597A (ja) 2012-12-21 2016-02-25 エピザイム，インコーポレイティド Ｐｒｍｔ５阻害剤およびその使用
US8940726B2 (en) 2012-12-21 2015-01-27 Epizyme, Inc. PRMT5 inhibitors and uses thereof
EP2935240A1 (en) 2012-12-21 2015-10-28 Epizyme, Inc. Prmt5 inhibitors and uses thereof
ES2792899T3 (es) * 2015-02-24 2020-11-12 Pfizer Derivados de nucleósidos sustituidos útiles como agentes anticancerosos

Also Published As

Publication number Publication date
ECSP17072987A (es) 2018-02-28
IL254409A0 (en) 2017-11-30
TWI615400B (zh) 2018-02-21
KR20170132871A (ko) 2017-12-04
TW201712022A (zh) 2017-04-01
PH12017502002A1 (en) 2018-03-26
HK1244007A1 (zh) 2018-07-27
AR104326A1 (es) 2017-07-12
US9840532B2 (en) 2017-12-12
CL2017002637A1 (es) 2018-04-20
CN107580602A (zh) 2018-01-12
JP6181889B1 (ja) 2017-08-16
JP2017125029A (ja) 2017-07-20
AU2016258485A1 (en) 2017-10-12
CR20170443A (es) 2017-11-07
EP3292128A1 (en) 2018-03-14
TN2017000459A1 (en) 2019-04-12
BR112017020336A2 (pt) 2019-05-14
EA201792169A1 (ru) 2018-03-30
PE20180231A1 (es) 2018-01-31
MA42036A (fr) 2018-03-14
JP2017525667A (ja) 2017-09-07
DOP2017000255A (es) 2018-01-15
WO2016178870A1 (en) 2016-11-10
SG11201708345XA (en) 2017-11-29
CA2981097A1 (en) 2016-11-10
US20160326208A1 (en) 2016-11-10
CO2017010727A2 (es) 2018-01-31

Similar Documents

Publication Publication Date Title
PH12017502002A1 (en) 5`-substituted nucleoside analogs
PH12020551332A1 (en) Imidazopyrimidines and triazolopyrimidines as a2a / a2b inhibitors
PH12020550901A1 (en) Macrocyclic compounds for treating disease
PH12019501959A1 (en) Therapeutic rna
MX2019001125A (es) Inhibidores de cinasa macrociclica.
PH12017501413A1 (en) Substituted nucleoside derivatives useful as anticancer agents
MX2022012013A (es) Composiciones y metodos para transduccion de tumores.
EA024630B9 (ru) Производные пиразола как ингибиторы ионных каналов, активируемых высвобождением кальция (crac)
PH12015502414A1 (en) Enhancer of zeste homolog 2 inhibitors
MX2022001310A (es) Compuesto de fenil-2-hidroxi-acetilamino-2-metil-fenilo.
MX2016014559A (es) Compuestos para el tratamiento de cancer.
MX370270B (es) Inhibidores de glucosilceramida sintasa para el tratamiento de enfermedades.
MX382092B (es) Compuestos heterocíclicos para el tratamiento de enfermedades.
MX2020009966A (es) Formas de dosificacion y usos terapeuticos de la l-4-cloro quinurenina.
MX2016015568A (es) Derivados de nucleosidos para el tratamiento del cancer.
MX2018011046A (es) Composiciones y metodos para tratar canceres.
MX2017006513A (es) Compuestos de tipo 1,9-diazaespiroundecano con actividad multimodal contra el dolor.
PH12017500910A1 (en) Use of sigma receptor ligands in osteoarthritis
MX2018007517A (es) Compuestos triciclicos y composiciones como inhibidores de quinasa.
GEP20197007B (en) Therapeutic agent for frontal lobe dysfunction
MX2017013669A (es) Composiciones para el tramiento del cancer.
MX2018000418A (es) Derivados de amida que tienen actividad multimodal contra el dolor.
GB2553684A8 (en) Ethynylxanthines, preparation and use for cancer treatment
WO2017049140A3 (en) Angiotensin (1-7) analogs and methods relating thereto